keyword
MENU ▼
Read by QxMD icon Read
search

oncology lymphoma

keyword
https://www.readbyqxmd.com/read/28646771/efficacy-of-alectinib-in-central-nervous-system-metastases-in-crizotinib-resistant-alk-positive-non-small-cell-lung-cancer-comparison-of-recist-1-1-and-rano-hgg-criteria
#1
Leena Gandhi, Sai-Hong Ignatius Ou, Alice T Shaw, Fabrice Barlesi, Anne-Marie C Dingemans, Dong-Wan Kim, D Ross Camidge, Brett G M Hughes, James C-H Yang, Javier de Castro, Lucio Crino, Hervé Léna, Pascal Do, Sophie Golding, Walter Bordogna, Ali Zeaiter, Ahmed Kotb, Shirish Gadgeel
BACKGROUND: Central nervous system (CNS) progression is common in patients with anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) receiving crizotinib. Next-generation ALK inhibitors have shown activity against CNS metastases, but accurate assessment of response and progression is vital. Data from two phase II studies in crizotinib-refractory ALK+ NSCLC were pooled to examine the CNS efficacy of alectinib, a CNS-active ALK inhibitor, using Response Evaluation Criteria in Solid Tumours (RECIST version 1...
June 21, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28644837/real-world-first-line-treatment-and-overall-survival-in-non-small-cell-lung-cancer-without-known-egfr-mutations-or-alk-rearrangements-in-us-community-oncology-setting
#2
Amy P Abernethy, Ashwini Arunachalam, Thomas Burke, Caroline McKay, Xiting Cao, Rachael Sorg, David P Carbone
PURPOSE: To establish a baseline for care and overall survival (OS) based upon contemporary first-line treatments prescribed in the era before the introduction of immune checkpoint inhibitors, for people with metastatic non-small cell lung cancer (NSCLC) without common actionable mutations. METHODS: Using a nationally representative electronic health record data from the Flatiron dataset which included 162 practices from different regions in US, we identified patients (≥18 years old) newly diagnosed with stage IV NSCLC initiating first-line anticancer therapy (November 2012- January 2015, with follow-up through July 2015)...
2017: PloS One
https://www.readbyqxmd.com/read/28643684/-adult-t-cell-leukemia-lymphoma-report-of-a-case-in-uruguay
#3
Matilde Boada, Sofía Grille, Andreina Brugnini, Natalia Trias, Cecilia Canesa, Lilián Díaz, Daniela Lens
Adult T-cell leukemia/lymphoma belongs to the group of mature T-cell malignancies according to the WHO classification. It constitutes a rare entity and has a strong association with infection by human T-lymphotropic virus 1. In Uruguay, this viral infection is very infrequent and, to our knowledge, no case of adult T-cell leukemia/lymphoma has been previously reported. We describe the case of a woman, immigrant from Peru, who presented with persistent lymphocytosis, intestinal parasitic diseases, and skin involvement...
2017: Medicina
https://www.readbyqxmd.com/read/28625332/considerations-of-developing-an-ngs-assay-for-clinical-applications-in-precision-oncology-the-nci-match-ngs-assay-experience
#4
Chih-Jian Lih, Naoko Takebe
Next generation sequencing (NGS) technologies have been widely adapted in clinical oncology by utilizing the profiled genetic mutation information to select patients and to guide the choice of target therapy. To fulfill the regulatory compliance, development of an NGS assay that will be used in clinical trials requires an analytical validation to meet its intend clinical use. NCI-MATCH trial is the largest precision oncology basket trial which uses a single NGS assay (NCI-MATHC NGS assay) to screen the actionable mutations in 6000 patients, who have relapsed/refractory solid tumors and lymphomas after standard systemic treatment, and assigns matched treatment...
May 2017: Current Problems in Cancer
https://www.readbyqxmd.com/read/28622960/treatment-of-peripheral-t-cell-lymphoma-in-community-settings
#5
Tatyana Feldman, Charles M Farber, Kelly Choi, Claudio Faria, Andre Goy, Jacqueline Connors, Dhakshila Paramanathan, Sukhi Kaur, Eric Schultz, Michael McGuire, Stuart L Goldberg
BACKGROUND: Peripheral T-cell lymphomas (PTCLs) represent a rare and heterogeneous group of malignancies that do not have consensus treatment recommendations. Strategies extrapolated from B-cell lymphoma have met with limited efficacy, although T-cell-specific salvage therapies have been recently developed. METHODS: To determine treatment patterns and associated outcomes in PTCL not otherwise specified (PTCL-NOS), anaplastic large T-cell lymphoma (ALCL), and angioimmunoblastic T-cell lymphoma (AITL), a retrospective analysis was undertaken at a large US community oncology network among patients treated between January 2010 and April 2015...
June 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28612375/outcome-of-adolescents-and-young-adults-compared-to-children-with-hodgkin-lymphoma-treated-with-response-based-chemotherapy-on-pediatric-protocols-a-children-s-oncology-group-report
#6
Karen S Fernández, Cindy L Schwartz, Lu Chen, Louis S Constine, Allen Chauvenet, Pedro A de Alarcón
PURPOSE: We evaluated the outcome of children (<15 years) versus that of adolescents and young adults (AYA; 15-≤ 21 years) treated for Hodgkin lymphoma (HL) in two Pediatric Oncology Group/Children's Oncology Group clinical trials, P9425 and P9426, that used dose-dense, response-based chemotherapy and reduced dose radiotherapy. PATIENTS AND METHODS: Subjects 21 years or younger with HL were eligible for these studies. Subjects with low-risk (stages IA, IIA, and IIIA1) without large mediastinal adenopathy biopsy-proven HL, eligible for P9426, were treated with two to four 28-day cycles of doxorubicin, bleomycin, vincristine, and etoposide (ABVE) chemotherapy and 25...
June 14, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28608996/prognostic-value-of-event-free-survival-at-12-and-24-months-and-long-term-mortality-for-non-hodgkin-follicular-lymphoma-patients-a-study-report-from-the-spanish-lymphoma-oncology-group
#7
Mariano Provencio, Ana Royuela, María Torrente, Marina Pollán, José Gómez-Codina, Pilar Sabín, Marta Llanos, Josep Gumá, Cristina Quero, Ana Blasco, David Aguiar, Francisco Ramón García-Arroyo, Javier Lavernia, Natividad Martínez, Manuel Morales, Álvaro Saenz-Cusi, Delvys Rodríguez, Virginia Calvo, Luis de la Cruz-Merino, Miguel Ángel de la Cruz, Antonio Rueda
BACKGROUND: Relatively few studies have analyzed the mortality of follicular lymphoma (FL) patients in comparison with a sex- and age-matched general population. This study analyzed the overall survival (OS) of patients with FL and compared their survival with the expected survival of a general population. METHODS: Patients diagnosed with FL were prospectively enrolled from 1980 to 2013. Standardized mortality ratios (SMRs) were obtained from yearly sex- and age-specific mortality rates in Spain, and OS was compared with age- and sex-matched general population data...
June 13, 2017: Cancer
https://www.readbyqxmd.com/read/28606732/constitutive-and-acquired-mechanisms-of-resistance-to-immune-checkpoint-blockade-in-human-cancer
#8
Matteo Bellone, Angela Rita Elia
Cancer immunotherapy with monoclonal antibodies directed against regulatory pathways in T lymphocytes has been revolutionizing medical oncology, and the clinical success of monoclonal antibodies targeting either cytotoxic T lymphocyte antigen-4 (CTLA-4) or program death-1 (PD-1) in patients affected by melanoma, Hodgkin's lymphoma, Merkel cell carcinoma, and head and neck, bladder, renal cell or non-small cell lung cancer is way beyond the most optimistic expectation. However, immune checkpoint blockade (ICB) has failed to arrest progression in a consistent amount of patients affected by those tumors, and various histological types, including breast, colon and prostate cancer, are less sensitive to this therapeutic approach...
June 2, 2017: Cytokine & Growth Factor Reviews
https://www.readbyqxmd.com/read/28604372/adaptive-region-growing-with-maximum-curvature-strategy-for-tumor-segmentation-in-18-f-fdg-pet
#9
Shan Tan, Laquan Li, Wookjin Choi, Min Kyu Kang, Warren D D'Souza, Wei Lu
Accurate tumor segmentation in PET is crucial in many oncology applications. We developed an adaptive region-growing (ARG) algorithm with a maximum curvature strategy (ARG_MC) for tumor segmentation in PET. The ARG_MC repeatedly applied a confidence connected region-growing algorithm with increasing relaxing factor f. The optimal relaxing factor (ORF) was then determined at the transition point on the f-volume curve, where the volume just grew from the tumor into the surrounding normal tissues. The ARG_MC along with five widely used algorithms were tested on a phantom with 6 spheres at different signal to background ratios and on two clinic datasets including 20 patients with esophageal cancer and 11 patients with non-Hodgkin lymphoma (NHL)...
July 7, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/28603407/simultaneous-tumor-segmentation-image-restoration-and-blur-kernel-estimation-in-pet-using-multiple-regularizations
#10
Laquan Li, Jian Wang, Wei Lu, Shan Tan
Accurate tumor segmentation from PET images is crucial in many radiation oncology applications. Among others, partial volume effect (PVE) is recognized as one of the most important factors degrading imaging quality and segmentation accuracy in PET. Taking into account that image restoration and tumor segmentation are tightly coupled and can promote each other, we proposed a variational method to solve both problems simultaneously in this study. The proposed method integrated total variation (TV) semi-blind de-convolution and Mumford-Shah segmentation with multiple regularizations...
February 2017: Computer Vision and Image Understanding: CVIU
https://www.readbyqxmd.com/read/28602129/from-the-children-s-oncology-group-evidence-based-recommendations-for-peg-asparaginase-nurse-monitoring-hypersensitivity-reaction-management-and-patient-family-education
#11
Deborah Woods, Kari Winchester, Alison Towerman, Katie Gettinger, Christina Carey, Karen Timmermann, Rachel Langley, Emily Browne
PEG-aspariginase is a backbone chemotherapy agent in pediatric acute lymphoblastic leukemia and in some non-Hodgkin lymphoma therapies. Nurses lack standardized guidelines for monitoring patients receiving PEG-asparaginase and for educating patients/families about hypersensitivity reaction risks. An electronic search of 6 databases using publication years 2000-2015 and multiple professional organizations and clinical resources was conducted. Evidence sources were reviewed for topic applicability. Each of the final 23 sources was appraised by 2 team members...
June 1, 2017: Journal of Pediatric Oncology Nursing: Official Journal of the Association of Pediatric Oncology Nurses
https://www.readbyqxmd.com/read/28598870/molecularly-targeted-agents-in-oculoplastic-surgery
#12
Richard C Allen
PURPOSE OF REVIEW: Significant advances have been made in oncology and rheumatology with the introduction of molecularly targeted agents (MTAs). MTAs consist of monoclonal antibodies and small molecule inhibitors. The purpose of this manuscript is to review the recent applications of MTAs to orbital, lacrimal, and eyelid disease. RECENT FINDINGS: The use of monoclonal antibodies has been described in the treatment of orbital vascular lesions, lymphoma, and squamous cell carcinoma...
June 8, 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/28596157/-18-f-fdg-pet-and-ct-scan-detect-new-imaging-patterns-of-response-and-progression-in-patients-with-hodgkin-lymphoma-treated-by-anti-pd1-immune-checkpoint-inhibitor
#13
Laurent Dercle, Romain-David Seban, Julien Lazarovici, Lawrence Schwartz, Roch Houot, Samy Ammari, Alina Danu, Véronique Edeline, Aurélien Marabelle, Vincent Ribrag, Jean-Marie Michot
The response evaluation criteria in patients with Hodgkin Lymphoma (HL) were designed for the assessment of chemotherapy and targeted molecular agents. We investigated the accuracy of 3-month-(18)F-FDG-PET/CT for the identification of HL patients (pts) responding to immune-checkpoint blockade by Anti-Programmed Death 1 antibodies (anti-PD1). We also reported the frequency of new immune patterns of response and progression. Methods: Retrospectively, we recruited consecutive HL patients treated by anti-PD1 (Pembrolizumab or Nivolumab) at Gustave Roussy, Villejuif, France, from 2013-2015...
June 8, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28594662/patient-derived-tumor-xenografts-of-lymphoproliferative-disorders-are-they-surrogates-for-the-human-disease
#14
Marco Pizzi, Giorgio Inghirami
PURPOSE OF REVIEW: Patient-derived tumor xenografts (PDTXs) have emerged as powerful platforms in medical oncology. A plethora of PDTXs were generated to study solid cancers, but limited data are as yet available on hematological diseases. The aim of this review is to describe the state of art of lymphoma PDTXs, discussing future directions for the development of integrated/personalized cancer programs. RECENT FINDINGS: In the last decades, several PDTXs of lymphoproliferative disorders have been produced...
July 2017: Current Opinion in Hematology
https://www.readbyqxmd.com/read/28590426/down-s-syndrome-and-triple-negative-breast-cancer-a-rare-occurrence-of-distinctive-clinical-relationship
#15
Nandini Dey, Amy Krie, Jessica Klein, Kirstin Williams, Amanda McMillan, Rachel Elsey, Yuliang Sun, Casey Williams, Pradip De, Brian Leyland-Jones
Down's syndrome (DS), the most common genetic cause of significant intellectual disability in children and adults is caused by the trisomy of either all or a part of human chromosome 21 (HSA21). Patients with DS mostly suffer from characteristic tumor types. Although individual patients of DS are at a higher risk for acute leukemia and testicular cancers, other types of solid tumors including breast cancers are mostly uncommon and have significantly lower-than-expected age-adjusted incidence rates. Except for an increased risk of retinoblastomas, and lymphomas, the risk of developing solid tumors has been found to be lower in both children and adults, and breast cancer was found to be almost absent (Hasle H...
June 7, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28575861/diagnostic-accuracy-of-pcr-for-detecting-alk-gene-rearrangement-in-nsclc-patients-a-systematic-review-and-meta-analysis
#16
Xia Zhang, Jian-Guo Zhou, Hua-Lian Wu, Hu Ma, Zhi-Xia Jiang
BACKGROUND: Anaplastic lymphoma kinase (ALK) gene fusion has been reported in 3~5% non-small cell lung carcinoma (NSCLC) patients, and polymerase chain reaction (PCR) is commonly used to detecting the gene status, but the diagnostic capacity of it is still controversial. A systematic review and meta-analysis was conducted to clarify the diagnostic accuracy of PCR for detecting ALK gene rearrangement in NSCLC patients. RESULTS: 18 articles were enrolled, which included 21 studies, involving 2800 samples from NSCLC patients...
May 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28561902/safety-and-pharmacokinetics-of-bendamustine-rapid-infusion-formulation
#17
Eric M Cheung, William J Edenfield, Bassam Mattar, Stephen P Anthony, Peter J Mutch, Brian Chanas, Mark Smith, Adrian Hepner
Bendamustine hydrochloride (BDM) is approved in the United States to treat chronic lymphocytic leukemia and relapsed indolent B-cell non-Hodgkin lymphoma. The first formulation marketed in the United States (original BDM) was a lyophilized product requiring reconstitution prior to dilution to the final admixture. A liquid formulation of BDM was subsequently introduced that did not require reconstitution before dilution. Both formulations are administered as a 500 mL admixture with a recommended infusion time of 30 or 60 minutes for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma, respectively...
May 31, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28556532/feline-large-granular-lymphocyte-lymphoma-an-italian-society-of-veterinary-oncology-sioncov-retrospective-study
#18
R Finotello, M E Vasconi, S Sabattini, C Agnoli, C Giacoboni, M Annoni, A Dentini, G Bettini, P Guazzi, D Stefanello, E Bottero, P Mesto, R Marinelli, C De Feo, L Marconato
Feline large granular lymphocyte (LGL) lymphoma is an uncommon subtype of lymphoma characterized by a grave prognosis and scarce response to chemotherapy. There are limited reports on clinico-pathological and prognostic factors. One-hundred and 9 cats with newly diagnosed LGL lymphoma that underwent initial staging (including hematology, serum biochemistry, thoracic radiographs and abdominal ultrasound), and followed-up were retrospectively evaluated. LGL lymphoma was localized within the gastrointestinal tract with or without extra-intestinal involvement in 91...
May 29, 2017: Veterinary and Comparative Oncology
https://www.readbyqxmd.com/read/28549594/-recommendations-for-the-organ-donation-from-patients-with-brain-or-medullary-primitive-tumors-on-behalf-of-the-association-of-the-neuro-oncologists-of-french-expression-anocef-and-the-club-of-neuro-oncology-of-the-french-society-of-neurosurgery
#19
Didier Frappaz, Emilie Le Rhun, Arnaud Dagain, Benoît Averland, Luc Bauchet, Alexandre Faure, Christian Guillaume, Sonia Zouaoui, François Provot, Florence Vachiery, Luc Taillandier, Khê Hoang-Xuan
Requests of organs to be transplanted increase. As a matter of urgency, it is not always easy to decide if a patient carrier of a brain tumor can be candidate in the donation. After a review of the literature, the members of the Association of the Neuro-oncologists of French Expression (ANOCEF) and the Club of Neuro-oncology of the French Society of Neurosurgery propose consensual recommendations in case of donor carrier of primitive tumor intra-cranial or intra-medullary. A contact with the neuro-oncologist/neurosurgeon will allow to discuss the indication in case of glioma of grade I/II/III, according to the grade, the current status (absence of progressive disease), the number of surgeries and of lines of treatment...
May 23, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28546703/histological-surprises-in-benign-cytologies-after-lymph-node-biopsy-surgeon-s-knife-improving-patient-care
#20
Mario Victor Newton, Rakesh S Ramesh, Suraj Manjunath, K ShivaKumar, Hemanth G Nanjappa, Ramu Damuluri, Elvis Peter Joseph, C Prasad
Lymphadenopathy can be due to multitude of causes. Owing to the high prevalence of infectious diseases in India, and malignancy being a life threatening cause for lymphadenopathy; accurate diagnosis is important in preventing delay or misdiagnosis and in improving patient care, thereby increasing longevity with quality. Fine needle aspiration cytology (FNAC) is the first line investigation commonly done. Should the doctor be contented with the benign FNAC or is a lymph node biopsy needed in this age? The aims of this study are the following: (1) to study the spectral pattern of lymph node biopsies done in a surgical oncology unit of tertiary care centre, (2) to assess the yield of malignant cases from lymph node biopsy and (3) to compare the reliability of benign FNAC with lymph node biopsy...
June 2017: Indian Journal of Surgical Oncology
keyword
keyword
63324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"